Pages that link to "Q57218945"
Jump to navigation
Jump to search
The following pages link to Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism (Q57218945):
Displaying 50 items.
- FGF23 in Acute and Chronic Illness (Q26778554) (← links)
- Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease? (Q27002431) (← links)
- Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease (Q27024043) (← links)
- FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease (Q27687769) (← links)
- Fibroblast Growth Factor-23-A Potential Uremic Toxin (Q28075648) (← links)
- The use of fibroblast growth factor 23 testing in patients with kidney disease (Q33835743) (← links)
- Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (Q34385273) (← links)
- Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study (Q34739121) (← links)
- Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial (Q35115090) (← links)
- Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis (Q35232118) (← links)
- Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism (Q35682152) (← links)
- Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency (Q35735678) (← links)
- FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis (Q35949319) (← links)
- Update on fibroblast growth factor 23 in chronic kidney disease (Q36210285) (← links)
- Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease (Q36225208) (← links)
- Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. (Q36432849) (← links)
- Changes in jawbones of male patients with chronic renal failure on digital panoramic radiographs (Q36667542) (← links)
- Fibroblast growth factor 23 and bone mineralisation (Q36756061) (← links)
- Phosphate Toxicity in CKD: The Killer among Us (Q36965142) (← links)
- Fibroblast growth factor-23: what we know, what we don't know, and what we need to know (Q37162723) (← links)
- A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study (Q37162734) (← links)
- Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats (Q37328071) (← links)
- Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism (Q37412861) (← links)
- Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review (Q37695914) (← links)
- FGF23 and PTH--double agents at the heart of CKD. (Q37996937) (← links)
- The role of FGF23 in CKD--with or without Klotho. (Q38020094) (← links)
- The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications (Q38053246) (← links)
- Cinacalcet hydrochloride for the treatment of hyperparathyroidism (Q38085702) (← links)
- FGF-23 and secondary hyperparathyroidism in chronic kidney disease (Q38123396) (← links)
- Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. (Q38141236) (← links)
- Defective skeletal mineralization in pediatric CKD. (Q38339007) (← links)
- Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. (Q38436799) (← links)
- Advances in pharmacotherapy for secondary hyperparathyroidism (Q38544533) (← links)
- Cinacalcet and Clinical Outcomes in Dialysis (Q38565049) (← links)
- Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. (Q38605841) (← links)
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. (Q38633258) (← links)
- Chronic Kidney Disease-Mineral and Bone Disorder in Asia (Q38635767) (← links)
- FGF23 from bench to bedside. (Q38728860) (← links)
- A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo (Q39037214) (← links)
- Calcimimetics and outcomes in CKD. (Q42727545) (← links)
- AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients (Q45367463) (← links)
- Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription (Q46101921) (← links)
- Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism (Q46921995) (← links)
- Severe secondary hyperparathyroidism and panoramic radiography parameters. (Q50701001) (← links)
- Correlation between hand/wrist and panoramic radiographs in severe secondary hyperparathyroidism. (Q50743231) (← links)
- Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis (Q51197552) (← links)
- Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study (Q58091341) (← links)
- TGF-Beta Signaling in Bone with Chronic Kidney Disease (Q58789309) (← links)
- Phosphate control in reducing FGF23 levels in hemodialysis patients (Q58797979) (← links)
- Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism (Q84847501) (← links)